COMMUNIQUÉS West-GlobeNewswire
-
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
21/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
21/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
21/10/2026 -
Leo International Precision Health AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution
21/10/2026 -
Rendever Introduces Nova, an AI Life Enrichment Assistant, to CommunityOS
21/10/2026 -
Major shareholder announcement - BlackRock, Inc.
21/10/2026 -
Organic & Natural Health Association Shares 5 Ways Americans Can Protect Their Health as Insurance Costs Rise
21/10/2026 -
Healthcare’s Financial Leaders Pledge Unprecedented Collaboration to Address America’s Healthcare Affordability Crisis
21/10/2026 -
Atalan to Present New Research on Measuring AI’s Real-World Impact and Predicting Nurse Turnover
21/10/2026 -
Science News unveils its list of 10 scientists making an impact on our world
21/10/2026 -
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
21/10/2026 -
New JAHA-Published EggNest® Study and Texas State Regulatory Variance Validate Shift Toward Apron-Free Workflows in the Interventional Lab
21/10/2026 -
Nobel Laureates Join China’s Brain-Health Conversation: Michael Levitt and May-Britt Moser
21/10/2026 -
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
21/10/2026 -
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
21/10/2026 -
Alignment Health Expands Medicare Advantage Plan to Nye County for 2027
21/10/2026 -
Grâce à l’IA, le KFSH anticipe la fréquentation des urgences 24 heures à l’avance et réduit de 42 % le délai d’attente avant la consultation médicale
21/10/2026 -
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
21/10/2026 -
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
21/10/2026
Pages